Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge and Kirkland & Ellis advises Baxter in connection with the acquisition of Gambro
Mandate

Vinge and Kirkland & Ellis advises Baxter in connection with the acquisition of Gambro

December 05, 2012

Vinge and Kirkland & Ellis advises the global medical technology company Baxter International Inc. (“Baxter”) in connection with the acquisition of Gambro AB for an enterprise value of SEK 26.5 billion. Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge acted as local counsel for Baxter. The Vinge team included Johan Winnerblad (partner), Jonas Bergström and Jonas Johansson together with, among others, Nicolina Kindblom, Gustav Jönsson, Rime Dreber, Emma Lindelöf, Daniel Unger, Helena Höök and Evelina Tejle.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025